LYEL NASDAQ
Lyell Immunopharma, Inc.
1W: +4.3%
1M: +3.9%
3M: -22.0%
YTD: -65.1%
1Y: -42.6%
3Y: -67.3%
5Y: -96.4%
$10.12
+0.81 (+8.70%)
Pre-Market: $9.66 (-0.46, -4.55%)
Weekly Expected Move ±10.3%
$7
$8
$9
$10
$11
Credit Risk of going bust: higher than 72% of companies Debt: 13.0% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the third-riskiest tenth, about 1 in 140 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.23 (down 98%), Lyell Immunopharma, Inc. would be worth roughly what it owes.
Total debt $36.9M against a stock market value of $248.0M.
Distance to default 3.28 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $18.5M (short-term plus half of long-term), stock volatility 79.5%; Altman Z'' -16.22. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.23 (down 98%), Lyell Immunopharma, Inc. would be worth roughly what it owes.
Total debt $36.9M against a stock market value of $248.0M.
Distance to default 3.28 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $18.5M (short-term plus half of long-term), stock volatility 79.5%; Altman Z'' -16.22. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
10 relationships10
As Filer
counterparties named
0
As Counterparty
mentioned by others
4
Rel. Types
2021-12-17
Earliest Filing
2025-11-10
Latest Filing
partner: 4
licensee: 2
target: 2
acquirer: 2
Counterparties (Filed by LYEL)
10 relationshipsCompanies named in LYEL's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Innovative Cellular Therapeutics Holdings Limited | — | licensee | Granted exclusive license for product candidates and received cash and stock | 2025-11-10 | View |
| Innovative Cellular Therapeutics, Inc. | — | licensee | Granted exclusive license for product candidates and received cash and stock | 2025-11-10 | View |
| ImmPACT Bio USA Inc. | — | target | Target company acquired by Lyell Immunopharma, Inc. via merger | 2024-10-31 | View |
| Inspire Merger Sub Inc. | — | acquirer | Wholly owned subsidiary of Lyell Immunopharma, Inc. used to effect the merger | 2024-10-31 | View |
| WT Representative LLC | — | partner | Representative and attorney-in-fact for ImmPACT securityholders in the Registration Rights Agreement | 2024-10-31 | View |
| ImmPACT Bio USA Inc. | — | target | Target company in a merger agreement to be acquired by Lyell Immunopharma, Inc. | 2024-10-24 | View |
| Inspire Merger Sub Inc. | — | acquirer | Wholly owned subsidiary of Lyell Immunopharma, Inc. used as the merger vehicle. | 2024-10-24 | View |
| WT Representative LLC | — | partner | Representative, agent, and attorney-in-fact for ImmPACT securityholders. | 2024-10-24 | View |
| GlaxoSmithKline Intellectual Property (No.5) Limited | — | partner | Co-signatory to Second Amendment to Collaboration and License Agreement | 2021-12-17 | View |
| Glaxo Group Limited | — | partner | Co-signatory to Second Amendment to Collaboration and License Agreement | 2021-12-17 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-09-10 | Other Events; Exhibits | View | |
| 2026-08-06 | Earnings Release; Exhibits | View | |
| 2026-06-15 | Shareholder Vote | View | |
| 2026-05-06 | Earnings Release; Exhibits | View | |
| 2026-03-12 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2026-03-09 | Departure/Election of Directors; Appointment of Officers; Financial Statements and Exhibits | View | |
| 2025-12-08 | Other Events | View | |
| 2025-12-05 | Amendments to Articles of Incorporation or Bylaws; Financial Statements and Exhibits | View | |
| 2025-11-12 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-11-10 | Entry into Material Definitive Agreement; Unregistered Sales of Equity Securities; Regulation FD Dis | Agreement | View |
| 2025-11-03 | Departure/Election of Directors; Appointment of Officers | View | |
| 2025-09-16 | Departure/Election of Directors; Appointment of Officers | View | |
| 2025-08-12 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-07-25 | Entry into Material Definitive Agreement; Unregistered Sales of Equity Securities; Regulation FD Dis | Agreement | View |
| 2025-06-26 | Unregistered Sales of Equity Securities | View | |
| 2025-06-17 | Other Events | View | |
| 2025-06-09 | Departure/Election of Directors; Appointment of Officers | View | |
| 2025-05-28 | Material Modification to Rights of Security Holders; Financial Statements and Exhibits | View | |
| 2025-05-21 | Submission of Matters to a Vote of Security Holders | View | |
| 2025-05-13 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR